Land: Armenia
Språk: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
clobetasol (clobetasol propionate)
GlaxoSmithKline Pharmaceuticals S.A.
D07AD01
clobetasol (clobetasol propionate)
0,5mg/g
cream
aluminium tube 25g
Prescription
Registered
2018-12-24
DERMOVATE CLOBETASOL PROPIONATE QUALITATIVE AND QUANTITATIVE COMPOSITION _DERMOVATE_ Cream and Ointment contains Clobetasol propionate 0.05 % w/w. CLINICAL INFORMATION INDICATIONS _DERMOVATE_ is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following: - Psoriasis (excluding widespread plaque psoriasis). - Recalcitrant dermatoses - Lichen planus - Discoid lupus erythematosus - Other skin conditions which do not respond satisfactorily to less potent steroids DOSAGE AND ADMINISTRATION _PHARMACEUTICAL FORM: CREAM AND OINTMENT _ _OINTMENT _ Ointments are especially appropriate for dry, lichenified or scaly lesions. _CREAM _ Creams are especially appropriate for moist or weeping surfaces. ADULTS, ELDERLY AND CHILDREN OVER 1 YEAR Apply thinly and gently rub in using only enough to cover the entire affected area once or twice a day for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient. Repeated short courses of _DERMOVATE_ may be used to control exacerbations. In more resistant lesions, especially where there is hyperkeratosis, the effect of _DERMOVATE_ can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion. If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated. Treatment should not be continued for more than 4 weeks. If continuous treatment is necessary, a less potent preparation should be used. The maximum weekly dose should not exceed 50 gms/week. ATOPIC DERMATITIS (ECZEMA) Therapy with _DERMOVATE_ cream and ointment should be gradually discont Les hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DERMOVATE, CLOBETASOL PROPIONATE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _DERMOVATE _Cream and Ointment contains Clobetasol propionate 0.05 % w/w. 3. PHARMACEUTICAL FORM Cream and Ointment. 4. CLINICAL PARTICULARS 4.1 INDICATIONS _DERMOVATE _is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following: - Psoriasis (excluding widespread plaque psoriasis). - Recalcitrant dermatoses - Lichen planus - Discoid lupus erythematosus - Other skin conditions which do not respond satisfactorily to less potent steroids 4.2 DOSAGE AND ADMINISTRATION _OINTMENT _ _ _ Ointments are especially appropriate for dry, lichenified or scaly lesions. _CREAM _ _ _ Creams are especially appropriate for moist or weeping surfaces. ADULTS, ELDERLY AND CHILDREN OVER 1 YEAR Apply thinly and gently rub in using only enough to cover the entire affected area once or twice a day for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient. Repeated short courses of _DERMOVATE _may be used to control exacerbations. In more resistant lesions, especially where there is hyperkeratosis, the effect of _DERMOVATE _can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion. If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated. Treatment should not be continued for more than 4 weeks. If continuous treatment is necessary, a less potent preparation should be used. The maximum weekly dose should not exceed 50gms/week. ATOPIC D Les hele dokumentet